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RNA polymerase II (RNAPII) subunit 5 (RPB5) is positioned close to DNA down-
stream of the initiation site and is the site of interaction with several regulators. Hep-
atitis B virus X protein (HBx) binds the central part of RPB5 to modulate activated
transcription, and TFIIF subunit RAP30 interacts with the same part of RPB5 that is
critical for the association between TFIIF and RNAPII. However the residues neces-
sary for these interactions remain unknown. Here we report systematic mutagenesis
of the central part of RPB5 using two-step alanine scanning libraries to pinpoint crit-
ical residues for its binding to RAP30 in the TFIIF complex and/or to HBx, and identi-
fied these residues in both mammalian cells and in an in vitro binding assay. Four
residues, F76, I104, T111 and S113, are critical for both TFIIF- and HBx-binding, indi-
cating the overlapping nature of the sites of interaction. In addition, V74 and N98 are
required for HBx-binding, and T56 and L58 are needed for RAP30-binding. Interest-
ingly the residues exposed to solvent, T111 and S113, are very close to the DNA, imply-
ing that two factors may modulate the interaction between DNA and RPB5.
Key words: alanine scanning, coactivation, HBx, RAP30, RPB5, TFIIF.
Abbreviations: RPB5, RNA polymerase subunit 5; HBx, hepatitis B virus X protein; RNAPII, RNA polymerase II;
RMP, RPB5-mediating protein; aa, amino acid.
Transcription is the primary regulatory step of eukaryotic
gene expression and is carried out by DNA-dependent
RNA Polymerase II (RNAPII) along with general tran-
scription factors (GTFs), transcription factors, and co-
factors (1–7). RNAPII is the ultimate target of transcrip-
tion factors and cofactors acting directly or indirectly to
modulate transcription. During the processes of tran-
scription, RNAPII changes partners or complexes with
which it interacts by altering its conformation. In this
context, several RNA polymerase subunits have recently
been reported to interact with these regulators (5).
RNAPII consists of 12 subunits that are well conserved
from yeast to human. Crystal structures and cryoelectron
microscopy have solved a subset of RNAPII transcription
complexes (3, 7–12) that provide deep insight into the
molecular basis of RNAPII transcription.
RNA polymerase II subunit 5 (RPB5) is part of the
lower jaw of RNAPII , and the exposed domain of RPB5
serves in interactions with transcriptional regulators
including Hepatitis B virus X protein (HBx), TFIIB,
Tip120, TFIIF subunit RAP30 and RMP/URI (3, 8, 13–
19). Human RPB5 consists of an exposed domain (aa 1 to
139) and an embedded domain (aa 140 to 210), which are
well conserved between yeast and human (20–22). There
is no interdomain interaction in the crystal models of
RPB5, implying the flexible nature of the exposed
domain relative to the embedded domain (8, 21). The
exposed domain seems to comprise two subdomains, the
N-terminal part (aa 1 to 47), and the central part of RPB5
(aa 57 to 139), with a short loop between the subdomains.
The N-terminal part is outside of the lower jaw, and the
central part of RPB5 is mostly inside the jaw and close to
the DNA downstream of the initiation site. The former is
critical for TFIIB-binding and the latter harbors the sites
of interaction with RAP30 and HBx, and probably RMP/
URI (8, 13, 15, 16, 18, 19).
TFIIF, a heterotetramer of RAP74 and RAP30, is a
unique general transcription factor that functions in ini-
tiation, elongation, and recycling of transcription (4, 18,
23, 24). TFIIF binds directly to RNAPII and also helps to
recruit the enzyme to the promoter (14, 25–28). TFIIF
can induce further bending and wrapping of the promoter
DNA against the mobile clamp of RNAPII during the for-
mation of the preinitiation complex (11, 29–32). The
direct interaction between the central region of RAP30
and the central part of RPB5 has been reported to con-
tribute to the association between TFIIF and RNAPII
(18), although other interactions between TFIIF and
RNAPII may occur during transcription (11).
HBx is a multifunctional viral regulator protein of
Hepatitis B Virus that coactivates activated, but not
basal, transcription in vivo and in vitro (17, 33, 34). The
direct interactions of RPB5 with HBx and TFIIB are crit-
ical for the coactivating ability of HBx (13, 15, 17), which
augments HBV replication positively (35) and modulatesVol. 138, No. 3, 2005 215 © 2005 The Japanese Biochemical Society.
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cellular protein, RPB5-mediating protein (RMP) (16) or
Unconventional RPB5-interacting protein (URI) (36),
which modulates transcription as a corepressor through
binding to RPB5, and counteracts transcriptional modu-
lation by HBx (16).
It remains unclear whether the sites of RPB5 targeted
by RAP30 and HBx are different or redundant. Here we
specified the residues critical for the interactions with
HBx and/or RAP30 by two-step alanine scanning with
mutant libraries of RPB5. Four residues, F76, I104, T111
and S113, were found to be essential for binding to the
two factors, indicating the overlapping nature of the
interactions.
MATERIALS AND METHODS
Plasmid Constructions—The plasmids pNKFLAG and
pNKGST derived from pSG5UTPL are FLAG-tagged and
GST-tagged mammalian expression vectors, respectively,
as reported. The plasmids pGENK1 and pGENKS are
bacterial expression vectors for GST-fused proteins (13,
16). The full-length coding region of human RPB5 (XAP4)
(1–210) was prepared as reported (13). Mutagenesis was
carried out by a splicing PCR method using AGCGAAT-
TCCATGGACGACGAGGAGGAG or AGTAGATCTCTA-
CTGCACCAG together with mutated oligonucleotide
primers (sequences available upon request). An alanine-
scanning method was used to construct RPB5 clustered
or single alanine substitution mutants to minimize the
effects of substituted amino acid residues (15, 37). The
positions of clustered mutants of RPB5 are shown in Fig.
1. The target sequence of 7 amino acid residues was
changed to AAASAAA for practical reasons in all clus-
tered mutants (cm). The second series of cm harboring
AAASA [cm I(s)] (spanning from the 1st to 5th residue of
the defining cm) and SAAA [cm II(s)] (spanning from the
4th to 7th residue of the defining cm) were constructed
using the NheI site–encoding SA sequence. Then single
alanine substitution mutants were constructed as fol-
lows: (i) if cm I(s) is defective, cm II(s) has no effect, first
three residues will be targeted to point mutant scanning;
(ii) if cm I(s) has no effect, cm II(s) is defective, last two
residues will be targeted to point mutant scanning; (iii) if
both cm I(s) and cm II(s) are defective, all seven residues
will be targeted to point mutant scanning. In the point
substitution mutants, the target residue was replaced
with alanine (A) in a two-step PCR scanning. All
sequences encoding full-length mutants of RPB5 were
inserted into the EcoRI and BglII/BamHI sites of pNK-
FLAG, pNKGST, pGENKS, and pYFLAG to construct
various expression vectors. All of the constructs were
sequenced by the dideoxy method using Taq sequencing
kits and a DNA sequencer (370A; Applied Biosystems
Inc. Co. Ltd.).
The plasmids pGST-RAP30 and His-ET-RAP74 were
gifts from R.G. Roeder. The truncation mutant of RAP30
cDNA, RAP30/d4, encodes the initiation codon followed
by amino acids 101 to 249, as reported (18).
The Escherichia coli histidine-tagged protein expres-
sion plasmid pLHis was derived from pET11d, by replac-
ing the NdeI–BamHI fragment with the annealed
complementary oligonucleotides TATGAATTCCATGAA-
GCTTGGATC and GATCCAAGCTTCATGGAATTCATA,
to introduce EcoRI, HindIII, and BamHI digestion sites.
The plasmid pLHis-HBx was constructed by inserting
the coding sequence of wild type HBx into the EcoRI and
BamHI sites of pLHis as reported (33).
Preparation of Recombinant Proteins—GST-fused pro-
teins were expressed in E. coli by induction with 0.4 mM
isopropyl-D-thiogalactopyranoside at 30°C for 3 h. The
cells were harvested and sonicated in PBST buffer (phos-
phate-buffered saline containing 1 mM DTT and 1%
Triton X-100) (16, 18). After centrifugation of the soni-
cated lysate, the supernatant was passed through DEAE
Sepharose, and GST-fused proteins were recovered with
glutathione-Sepharose 4B beads (Amersham Biosciences,
Inc.) at room temperature for 1 h. The beads were sedi-
mented, washed four times with an excess amount of
PBST buffer, and then eluted with 10 mM of reduced glu-
tathione in 50 mM Tris-HCl (pH 8.0). The eluted solution
was dialyzed against buffer B [100 mM Tris-HCl (pH
8.0), 150 mM NaCl, and 1mM DTT], then divided into
aliquots and stored at –80°C.
The His-tagged HBx protein was expressed in BL21
(DE3)/pLys using 0.7 mM isopropyl-D-thiogalacto-
pyranoside for 3 h at 27°C. The cell pellet was harvested
and washed, and resuspended in precleared buffer [50
mM sodium phosphate (pH 8.0), 500 mM NaCl, 10%
glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mM β-
mercaptoethanol, and 1% Triton X-100]. The suspension
was sonicated on ice and centrifuged at 12,000 × g for 15
min. The pellet was suspended in denaturing binding
buffer (100 mM sodium phosphate, 10 mM Tris-HCl, and
8 M urea) with the pH adjusted to 8.0 using HCl. The
lysate was centrifuged at 12,000 × g for 5 min, and the
cleared lysate was subjected to affinity binding to nickel
resin (Qiagen) preequilibrated with denaturing binding
buffer. The resin was washed once with denaturing bind-
ing buffer then several times with denaturating buffer
mixed with increasing amounts of bridge buffer (100 mM
sodium phosphate, 10 mM Tris-HCl, 2 mM DTT, 1 M
Fig. 1. Clustered substitution mutants (cm) of human RPB5.
The amino acid sequence of human RPB5 and a mutant library of
human RPB5 were constructed. The target of 7 amino acid residues
was changed to AAASAAA. Names of clustered mutants (cm) are
shown under two-headed arrows with numbers corresponding to
the number of the first of the 7 amino acid residues substituted with
AAASAAA in the human RPB5 open reading frame.J. Biochem.
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finally washed with bridge buffer. The bound His-HBx
was eluted with native elution buffer [50 mM sodium
phosphate (pH 8.0), 500 mM NaCl, 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride, 10 mM β-mercapto-
ethanol, 1% Triton X-100, and 500 mM imidazole].
Eluted solutions were combined and dialyzed against
buffer C [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10%
glycerol, 1 mM DTT, and 0.1% Triton X-100], and stored
at –80°C in aliquots.
FLAG-tagged proteins were expressed in BL21 by
induction with 0.4 mM isopropyl-D-thiogalacto-
pyranoside at 30°C for 3–6 h. The cells were harvested
and sonicated in 50 mM Tris-HCl (pH 8.0), 150 mM
NaCl, and 0.1% Triton X-100. After centrifugation, the
supernatant was stored at –80°C. FLAG-tagged proteins
were purified by incubating the supernatant with anti-
FLAG M2 resin (Kodak Scientific Imaging Systems) and
washing several times. The bound proteins were eluted
with buffer containing FLAG peptide [0.2 mg/ml FLAG
peptide, 50 mM Tris-HCl (pH 8.0), and 150 mM NaCl].
Eluted solutions were combined and dialyzed.
Antibodies—Anti-FLAG M2 and anti-His monoclonal
antibodies were purchased from Kodak Science Imaging
Systems. Anti-GST monoclonal antibody was obtained
from ZYMED Laboratories.
In Vitro GST Resin Pull-Down Assays—Approximately
1 µg of GST or GST-fused protein immobilized on 20 µl of
glutathione-Sepharose 4B preblocked in 1% bovine serum
albumin was incubated with 0.2 µg of FLAG-tagged pro-
teins or 0.5 µg of His-tagged proteins in 0.5 ml of GBT
buffer [10% glycerol, 50 mM Hepes-NaOH (pH 8.0), 170
mM KCl, 7.5 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, and
1% Triton X-100] for 3 h on a rotator at 4°C. After being
Fig. 2. Amino acid sequences
of RPB5 critical for HBx-
binding as analyzed in vivo
and in vitro. (A–C) In vivo
assays: COS1 cells were trans-
fected with pNKGST-HBx alone
in the absence of pNKFLAG-
RPB5 (mock) (lane 1), or transi-
ently cotransfected with the
mammalian expression vectors
pNKGST and pNKFLAG-RPB5
wild type (WT) (lane 2) or
pNKGST-HBx and pNKFLAG-
RPB5 wild type (WT) or different
cm RPB5 as indicated at the top
(lanes 3 to 11). (A) Total lysates
were separated by SDS-PAGE
and subjected to Western blot
analysis with α-FLAG mono-
clonal antibody (input). (B) Cell
lysates were pull-downed with
glutathione resin. After washing,
the bound proteins were detected
with an α-FLAG monoclonal
antibody. (C) The nitrocellulose
membranes used for Western blot
analysis with the α-FLAG anti-
body were reprobed with an α-
GST antibody. (D and E) In vitro
assays: (D) Purification of bacte-
rially expressed GST, GST-RPB5
wild type (WT) or different clus-
tered mutants as indicated. The
GST (lane 1) and GST-RPB5 WT
(lane 2) or mutant RPB5 (lanes 3
to 10) proteins were expressed in
E. coli and purified. Between 0.4
and 1 µg of each purified protein
was analyzed by SDS-PAGE and
stained with Coomassie Brilliant
Blue. (E) Interaction of RPB5 and
HBx proteins in vitro. Approxi-
mately 1 µg of bacterial GST or
bacterial recombinant GST-fused
RPB5 wild type (WT) or cm pro-
teins was immobilized on glu-
tathione resin and incubated
with 0.2 µg of His-HBx protein in
GBT buffer for 2 h at 4°C. Pull-
down assays and Western blot analysis were carried out with an α-His monoclonal antibody. Input (lane 1) and lanes 2 to 11 showed before
and after the pull-down assay, respectively. Each experiment was repeated at least three times and the data were reproducible.Vol. 138, No. 3, 2005
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were eluted, fractionated by 12% SDS-PAGE, and sub-
jected to Western blot analysis using anti-FLAG mono-
clonal antibody (M2) or anti-His monoclonal antibody.
Preparation of Cell Extract, Coprecipitation with
Glutathione-Sepharose 4B Resin, and Western Blot
Analysis—The transient transfection of COS1 cells was
carried out by standard CaCl2-mediated transfection.
The cells were harvested, washed, and sonicated in lysis
buffer [10% glycerol, 20 mM HEPES (pH 7.9), 50 mM
KCl, 0.4 M NaCl, 1 mM MgCl2, 0.1 mM dithiothreitol, 0.1
mM EDTA, 9 mM CHAPS, 0.5 mM phenylmethylsulfonyl
fluoride, and 10 µg/ml aprotinin and leupeptin], and then
centrifuged. The total cell lysates were stored at –80°C.
Total cell lysates were diluted with 4 times the volume of
buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, and
0.05% Tween 20] and incubated with 50 µl of glutathione-
Sepharose 4B beads for 3 h on a rotator at 4°C. After
extensive washing, the bound proteins were eluted,
fractionated by 15% SDS-PAGE, transferred onto nitro-
cellulose membranes, and subjected to Western blot anal-
ysis with the anti-FLAG M2 antibody. The proteins were
visualized by enhanced chemiluminescence (ECL)
according to the manufacturer’s instructions (Amersham
Biosciences). The nitrocellulose membranes used for
Western blot analysis with anti-FLAG monoclonal anti-
body were reprobed with anti-GST monoclonal antibody
(Zymed Laboratories Inc.) according to the manufac-
turer’s instructions (Amersham Biosciences).
Cell Culture and Transient Transfection—COS1 cells
(a monkey kidney cell line) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM; Invitrogene Co) sup-
plemented with 5% fetal calf serum (FCS; CELLect R
GOLD) and 20 mg/ml antibiotics (ampicillin and kana-
mycin; Meigi Co. Ltd ) and maintained in an incubator
with 5% CO2 at 37°C.
RESULTS
Amino Acid Sequences of the Central Part of RPB5 Nec-
essary for HBx-Binding In Vivo and In Vitro—The HBx-
binding region has been mapped within the central part
of RPB5 using various versions of truncation mutants
(15). To specify the amino acid sequence(s) and amino
acid residue(s) critical for HBx-binding, we applied a two-
step alanine scanning method using clustered substitu-
tion mutants (cm) and point substitution mutants (pm).
A cm library of human RPB5 covering aa 21 to 132 was
constructed by systematically substituting 7 amino acid
residues in a row with AAASAAA as shown in Fig. 1.
The ability of these cm RPB5 proteins to bind HBx was
examined with lysates of mammalian cells transiently
Fig. 3. Amino acid residues of
RPB5 critical for the HBx-
binding as analyzed in vivo
and in vitro. The experiments
were carried out as in Fig. 2
except that pNKFLAG-RPB5
harboring a single amino acid
substitution (pm) as indicated at
the top was used. (A–C) In vivo
assays: (A) Western blot analy-
sis of total lysates with an α-
FLAG monoclonal antibody. (B)
Western blot analysis of recov-
ered proteins bound to glutath-
ione resin with the α-FLAG
monoclonal antibody. (C) The
nitrocellulose membranes used
for Western blot analysis with
the α-FLAG antibody were rep-
robed with an α-GST antibody.
(D and E) In vitro assays: (D)
Purified bacterially expressed
GST-RPB5 pm proteins were
separated by SDS-PAGE and
stained with Coomassie Bril-
liant Blue. (E) Recovered His-
HBx protein bound to GST or
GST-RPB5 pm protein detected
with an α-His monoclonal anti-
body. Each experiment was
repeated at least three times
and the data were reproducible.J. Biochem.
Mutational Analysis of RPB5 219coexpressing GST-HBx and each FLAG-RPB5 cm protein
in vivo. COS1 cells were transfected with the mammalian
expression vectors and the cell lysates were pull-downed
with glutathione resin. GST-HBx recovered FLAG-RPB5
while GST alone did not (Fig. 2B, lanes 2 and 3). The
specific interaction of two proteins was also detected with
a different combination of tagged proteins (data not
shown). Under these conditions, four cm proteins of
RPB5 (cm 70, cm 98, cm 105, and cm 112) were not recov-
ered with HBx (Fig. 2B lanes 4, 8, 9, and 10, respec-
tively), although the other three cm proteins were recov-
ered similar to the wild type RPB5, and cm 91 was
recovered, but inefficiently (Fig. 2B, compared lane 3,
and 7 with lanes 5, 6, and 11, respectively). This result
was not due to different expression levels of proteins and/
or the efficiency of GST pull-down since the recovery of
GST-fused proteins was similar (Fig. 2C) and the
expression levels of FLAG-RPB5 wild type (WT) and
clustered mutants were similar (Fig. 2A). Each experi-
ment was repeated at least three times and the data are
reproducible.
To confirm the binding properties of cm mutants to
HBx in vivo, we performed an in vitro pull-down assay.
Bacterially expressed wild type and cm GST-RPB5 were
bound to glutathione resin (Fig. 2D) and subjected to
binding assays with purified His-tagged HBx (as
described in “MATERIALS AND METHODS”). To purify the
HBx protein expressed in vitro, the denatured followed
by renaturation method is better than the native method
(see details of purification in “MATERIALS AND METHODS”).
The bound HBx was subjected to Western blot analysis
with anti-His antibody. Consistent with the result in
vivo, we observed that the four cm RPB5 (cm 70, cm 98,
cm 105, and cm 112) were unable to interact with HBx
(Fig. 2E lanes 4, 8, 9, and 10, respectively). The other cm
mutants retained the ability to interact with HBx,
although the amount of protein recovered was not the
same for each mutant (Fig. 2E lanes 5, 6, 7, 11 and data
not shown). Four sequences of RPB5 (cm70, cm98, cm105
and cm112) critical for HBx-binding in vivo and in vitro
are in two different areas within the central part of RPB5
(aa 53 to 136).
Interaction between HBx and Alanine Point Mutant
(pm) RPB5 In Vivo and In Vitro—To identify residues
critical for binding HBx within the four cm mutants, we
constructed a second series of cm mutants harboring
AAASA and SAAA in the target sequence using the NheI
site–encoding SA sequence and analyzed them for pro-
tein–protein interactions (data not shown). Then single
alanine substitution mutants covering the sequence(s)
were constructed as explained in “MATERIALS AND METH-
ODS.” Similar experiments with the pm mutant series of
RPB5 were conducted in vivo and in vitro. We failed to
detect any interaction of HBx with RPB5 having V74A,
I104A, T111A, or S113A in both the in vivo and in vitro
assays (Fig. 3B, lanes 1, 6, 8, and 10, respectively; Fig.
3E, lanes 2, 7, 9, and 11, respectively). RPB5 harboring
F76A or N98A are severely affected in vivo and com-
pletely defective in vitro in their ability to interact with
HBx (Fig. 3B, lanes 3 and 4, respectively; Fig. 3E, lanes 4
and 5, respectively). On the other hand, none of the other
residues listed in Table 1 impaired the HBx interaction
(Fig. 3B, lanes 2, 5, 7, and 9; Fig. 3E, lanes 3, 6, 8, and 10;
and data not shown). Taken together, the results of the
experiments with coexpressed proteins in COS1 cells are
consistent with those with purified bacterial proteins in
vitro, indicating that the RPB5 residues critical for HBx
interaction are V74, F76, N98, I104, T111, and S113.
Interaction of RPB5 and (RAP30) TFIIF Proteins In
Vivo and In Vitro Analyzed with cm and pm Mutants of
RPB5—Previously we reported a direct interaction
between RPB5 and subunit RAP30 of TFIIF (18); how-
ever, the residues within RPB5 responsible for this inter-
action remain unknown. In this study, we addressed the
question of which sequences in the central part of RPB5
are required for the interaction between RAP30 in the
TFIIF complex and RPB5. To this end, COS1 cells were
cotransfected with mammalian plasmids expressing two
subunits of TFIIF: GST-RAP30 and FLAG-RAP74
together with wild type or one of the cm mutants of
FLAG-RPB5. The cell lysates were subjected to GST pull-
down with glutathione resin, and the recovered FLAG-
tagged RPB5 and RAP74 were detected immunologically
using an anti-FLAG monoclonal antibody. All the clus-
tered mutants of RPB5 were expressed equally upon
transfection into COS1 cells, and GST-RAP30 in each
combination of cotransfection was similarly recovered by
GST pull-down (Fig. 4, A and C). GST-RAP30, but not
GST alone, recovered FLAG-RPB5 and FLAG-RAP74
(Fig. 4B, lanes 2 and 3). The five cm mutants (cm 56, cm
70, cm 98, cm 105, and cm 112) were impaired in their
interaction with RAP30 in the TFIIF complex (Fig. 4B,
Table 1. Summary of RPB5-binding abilities.
a(++): binding positive; (–): binding negative.
Mutated 
human RPB5 residue HBx RAP30 (TFIIF)
Mutated 
human RPB5 residue HBx RAP30 (TFIIF)
T56A ++a – I99A ++ ++
D57A ++ ++ T100A ++ ++
L58A ++ – R101A ++ ++
D70A ++ ++ L103A ++ ++
Q71A ++ ++ I104A – –
M72A ++ ++ V105A ++ ++
F73A ++ ++ M110A ++ ++
V74A – ++ T111A – –
F75A ++ ++ P112A ++ ++
F76A – – S113A – –
N98A – ++Vol. 138, No. 3, 2005
220 T.T.T. Le et al.lanes 6, 8, 12, 13 and 14, respectively), although similar
amounts of RAP74 were recovered in the presence or
absence of wild type or mutant FLAG-RPB5. In contrast,
the other clustered mutants of RPB5 did show an ability
to bind TFIIF similar to that of the wild type RPB5 (Fig.
4B, lanes 3, 4, 5, 7, 9, 10, 11, 15 and data not shown).
Interestingly, all five of these cm mutants, except cm 56,
are not only defective in TFIIF-binding but also HBx-
binding (Fig. 2), indicating that overlapping sequences
are involved in the bindings to the two factors.
As previously reported, the N-terminus and the middle
part of subunit RAP30 can interact independently with
RPB5, although the former is masked by RAP74 in the
TFIIF complex (18). Therefore, the middle part of RAP30,
the construct RAP30 d4 (aa 101 to 249), was tested for
binding. It could bind RPB5 regardless of the presence or
absence of RAP74, a binding consistent with a previous
report (data not shown). Based on this observation, next
we used RAP30 d4 (aa 101 to 249) for the pull-down assay
in vitro to evaluate its ability to bind bacterially
expressed and purified wild type or cm RPB5. As shown
in Fig. 4D, all proteins except cm 56, cm 70, cm 98, cm
105, and cm 112, were recovered with GST-RPB5
bounded resin. Although we observed that cm 63, cm 84,
cm 91 showed weaker binding ability (Fig. 4D, compared
lanes 3, 4, 5, 9 and 15 with lanes 7, 10, and 11).
Using the same method as described in “MATERIALS
AND METHODS” to pinpoint critical residues of RPB5 for
RAP30-binding, we further constructed mutants of RPB5
with point alanine substitutions and examined their abil-
ity to interact with RAP30 (subunit of TFIIF) both in vivo
and in vitro. The six pm mutants of RPB5 (T56A, L58A,
F76A, I104A, T111A, and S113A) were clearly defective
in both RAP30-binding in the TFIIF complex in vivo and
in RAP30-binding using RAP30 d4 (which binds RPB5
regardless of the presence or absence of RAP74) in vitro
(Fig. 5B, lanes 1, 3, 5, 7, 9, and 11, respectively; Fig. 5D,
lanes 2, 4, 6, 8, 10, and 12, respectively). In contrast,
other pm mutants of RPB5 listed in Table 1 were able to
bind (Fig. 5B, lanes 2, 4, 6, 8 and 10; Fig. 5D, lanes 3, 5, 7,
9, and 11; and data not shown). Interestingly, among
them, in the in vivo experiment, two pm mutants, D57A
and P112A, exhibited much weaker ability to bind RAP30;
however, in vitro, pm mutant L103A exhibited weaker
interaction, suggesting that the GST pull-down assay
with two purified proteins in vitro may be not the same
as the GST pull-down of total cell lysate proteins in vivo.
Position of Residues Critical for the Interaction of
Human RPB5 with HBx/RAP30—Collectively, in the
central part of human RPB5, we identified six residues
critical for the interaction with HBx and six residues
indispensable for the interaction with RAP30. Interest-
ingly, among them, four residues (hF76, hI104, hT111,
and hS113) are required for the interactions with both
HBx and RAP30 in the TFIIF complex, and are conserved
the among human and yeast proteins (Table 1). The
Fig. 4. Amino acid sequences of RPB5 critical for RAP30-bind-
ing in the TFIIF complex as analyzed in vivo and in vitro. (A–
C) In vivo assays: Experiments were conducted in COS1 cells as
described in Fig. 2, A–C, except that COS1 was transiently cotrans-
fected with the mammalian expression vectors pNKGST-RAP30 and
pNKFLAG-RAP74 in the absence of pNKFLAG-RPB5 (mock) (lane
1), or together with pNKFLAG-RPB5 WT or cm as indicated. (D) In
vitro assays: Recovered bacterially expressed FLAG-RAP30 d4 (see
text in detail) bound to GST or GST-RPB5 WT or cm protein preb-
ound to glutathione resin was detected by Western blot analysis with
an α-FLAG antibody. Each experiment was repeated at least three
times and the data were reproducible.J. Biochem.
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and the corresponding conserved residues in yRPB5 are
shown in Fig. 6. Among the four conserved residues, yF82
(hF76) is juxtaposed in a β-sheet [designated A2 (21)] in
parallel with a β-sheet (A3) harboring yI109 (hI104),
which is close to yF82 (hF76). Amino acids yT117 (hT111)
and yS119 (hS113) are at the top of the exposed helix or
in the loop region (Fig. 6), and are the nearest neighbors
of yP118 (hP112), which has been proposed to be one of
the residues closest to the DNA. The two residues specific
for RAP30-binding, hT56 and hL58, are in the loop
between the N-terminal part and the central part of
RPB5, and are not conserved among human and yeast.
The two residues specific for HBx interaction, yV80
(hV74) and yN104 (hN98), are in A3 and in a loop
between a helix (α5) and A3.
DISCUSSION
Here, we report six residues (V74, F76, N98, I104, T111
and S113) critical for HBx-binding, and six residues (T56,
L58, F76, I104, T111 and S113) critical for RAP30-bind-
ing by RPB5. Interestingly, four of these residues are
redundant for RAP30- and HBx-binding, strongly imply-
ing that the two factors compete with each other for
RPB5-binding. In this context, HBx may inhibit or delay
a step in transcription in which the direct interaction
between RPB5 and TFIIF is involved. TFIIF has several
contact sites for RNAPII during initiation and elongation
Fig. 5. Amino acid residues of RPB5 critical for the RAP30-
binding in the TFIIF complex as analyzed in vivo and in vitro.
(A–C) In vivo assays: The experiments were conducted in COS1 cells
as described in Fig. 4 except that pNKFLAG-RPB5 pm as indicated
at the top was used. (D) In vitro assays: bacterially expressed GST-
RPB5 proteins with a single amino acid substitution as indicated
were used as described in Fig. 4 and Western blot analysis was car-
ried out with an α-FLAG monoclonal antibody. Each experiment was
repeated at least three times and the data were reproducible.
Fig. 6. Position of the newly identified residues in the crystal
model of RPB5. The corresponding conserved amino acid residues
predicted in Saccharomyces cerevisie RPB5 are shown in yellow
(except residues 56 to 58 belonging to a non-conserved region), and
the amino acid residues of human RPB5 essential for binding HBx
and the RAP30 subunit of TFIIF: threonine 56 (T56), leucine 58
(L58), valine 74 (V74), phenylalanine 76 (F76), asparagine 98
(N98), isoleucine 104 (I104), threonine 111 (T111), and serine 113
(S113), are shown in parentheses.Vol. 138, No. 3, 2005
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action of RPB5 and TFIIF may be critical for activated
transcription. Another possibility is that the central
region of the exposed domain covering aa 72 to 120 may
be an important surface for unidentified factors (as dis-
cussed below).
The central part of RPB5 (aa 53 to 136), proximal to
DNA downstream of the promoter (see Fig. 6), acts in
communication with several transcriptional regulators,
the TFIIF subunit RAP30, HBx and a novel corepressor
RMP/URI (8, 13, 15, 16, 18, 20, 21, 36, 38). We previously
identified HBx as a transcriptional coactivator through
its direct interaction with the central part of RPB5 (15,
17, 33, 34). The putative role of human RPB5 in activated
transcription is consistent with the reported role of yeast
RPB5 in the activated transcription of some promoters
(38), although it remains uncertain how RPB5 is involved
in activated transcription but not in basal transcription.
By two-step scanning with clustered and point alanine
substitution(s) libraries, we dissected the central part of
hRPB5 to address whether the sequence and residues
needed for RAP30-binding and HBx-binding are redun-
dant. In this paper, the interaction of RPB5 with HBx
and TFIIF was examined in vitro and in vivo with RPB5
and its partner co-expressed transiently in cells. The
interaction of RPB5 in RNAPII with these factors could
be elucidated since ectopically expressed RPB5 can be
efficiently incorporated into RNAPII (data not shown).
As RPB5 is well conserved between yeast and human
(8, 10, 13, 15, 18, 21, 22, 38, 39), and the topology of the
preinitiation complex is remarkably similar in the two
species as analyzed by cross-link experiments and cryoe-
lectron microscopy (11, 12, 32), the relevance of the posi-
tions of the conserved residues in human RPB5 were
evaluated on basis of the yeast crystal model (Fig. 6). The
results suggest that the rigid property of the four-
stranded β-sheet may be important for the structural
integrity of the central part of RPB5 (aa 53 to 144 of
yRPB5 or aa 53 to 139 of hRPB5). All residues except
T117 and S119 are non-charged and hydrophobic in the
four-stranded mixed β-sheet. As all the RPB5 residues
critical for binding RAP30 and/or HBx are conserved
between yeast and human except aa 56 to 58, we next
addressed the biological role of the six conserved residues
in yRPB5 by introducing point mutations in yeast in
place of the wild type counterpart. The yeast rpb5 series
of alanine/glycine substituted point mutant alleles was
generated by two-step PCR mutagenesis. The mutations
had no influence on cell viability but affected yeast cell
growth, especially at suboptimal temperatures (ts or/and
cs phenotype) (unpublished data). These results clearly
support the notion that the conserved residues of RPB5
required for RAP30-binding as well as HBx-binding play
an important role in cell growth in yeast. Interestingly,
the two charged residues, T117 and S119 of yRPB5 (T111
and S113 of hRPB5), are exposed to the solvent, and are
the nearest neighbors of the proline (yP118) that has
been reported to be closest to the DNA (8). We identified
the DNA-binding properties of hRPB5, and showed that
T111 and S113, but not P112, are critical or important for
DNA-binding (Zhang S. and Murakami S. et al, in a sepa-
rate manuscript). DNA has been reported to wrap around
the yeast and human RNAPII complex (9, 29, 30, 32), and
TFIIF forms multiple DNA contacts, spanning the DNA
from upstream to downstream of the promoter as
detected in cross-linking experiments (11, 23, 30, 32). In
that context, it is possible that both TFIIF and HBx may
modulate the interactions of RNAPII and DNA by pre-
venting RPB5 from accessing DNA downstream of the
initiation site. In this respect, it remains to be addressed
whether RPB5 is involved in recognition of a novel down-
stream promoter element, MTE (motif ten element), that
is conserved from Drosophila to human, as recently
reported (40).
We further defined the sequences of HBx that are
important for RPB5-binding (Le T. and Murakami S. et
al., unpublished data). All sequences are in the coactiva-
tion domain of HBx, but, interestingly, they are much
narrower than those necessary for the coactivation func-
tion of HBx as analyzed with the clustered mutant
library of HBx (35). The results imply that multiple part-
ners are necessary for the coactivation or transactivation
function of HBx, in addition to RPB5 as reviewed (17).
RMP/URI (16, 36) is another factor that requires the
central part of RPB5 for interaction. Three out of the four
residues critical for the binding of both RAP30 and HBx
seem also to be indispensable for the binding of RMP/URI
(in preparation). Gstaiger, et al. clearly demonstrated
that RMP/URI belongs to a prefoldin (PFD) family whose
members are able to assemble into molecular chaperone
complexes (36), and that yeast and human RMP/URIs
both seem to be targets of nutrient signaling controlled
by mTOR kinase in the cytoplasm (19, 36). Therefore, one
possibility is that the role of RPB5 in activated transcrip-
tion is not due to the function of RPB5 assembled in
RNAPII, and that HBx may induce the dissociation of the
cytoplasmic RPB5 and RMP/URI complex and facilitate
the assembly of nuclear RPB5 in RNAPII as HBx can
inhibit the binding between RPB5 and RMP/URI (unpub-
lished data). Recently, we reported the nuclear role of
RMP/URI in a complex with DMAP1, DNA methyl-
transferase 1-interacting protein, and showed that this
complex exhibits corepressor activity (19). In this con-
text, it seems possible that HBx releases the corepressor
complex RMP and DMAP1, and facilitates activated
transcription. The role of RPB5 in activated transcription
remains to be elucidated.
Taken together, the central part of RPB5 proximal to
DNA downstream of the promoter can be a target of sev-
eral transcriptional regulators that may interfere with
the interaction between the exposed domain of RPB5 and
DNA.
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